Still's Disease Market

Market Overview:

The 7 major Still's disease markets reached a value of USD 1.33 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1.92 Billion by 2035, exhibiting a growth rate (CAGR) of 3.41% during 2025-2035.

The Still’s disease market has been comprehensively analyzed in IMARC's new report titled "Still’s Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Still's disease is a rare inflammatory condition, categorized as a systemic autoinflammatory disorder, affecting both children (as systemic juvenile idiopathic arthritis) and adults. It typically presents with high, spiking fevers, a salmon-pink rash, joint pain or swelling, sore throat, and fatigue. The disease has two main types: adult-onset Still's disease (AOSD) and the juvenile form. Diagnosis is challenging, relying on clinical evaluation and exclusion of other conditions, supported by elevated inflammatory markers like CRP or ESR and sometimes ferritin. Imaging may reveal joint involvement. Treatment aims to manage inflammation and prevent complications, using nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressants such as methotrexate or biologics targeting IL-1 or IL-6. Early intervention is critical to minimize long-term damage to joints and organs, enhancing the patient's quality of life.

The increasing incidences of bacterial or viral infections that cause abnormal antibody responses to a harmful antigen are primarily driving the Still's disease market. In addition to this, the rising cases of autoimmune diseases, which result in an overreactive immune system attacking healthy tissues and cells in the body, are also bolstering the market growth. Moreover, the widespread adoption of several effective medications, such as nonsteroidal anti-inflammatory drugs and steroids, to reduce inflammation, control symptoms, as well as improve quality of life among patients, is acting as another significant growth-inducing factor. Besides this, the inflating application of physical therapies, owing to their numerous benefits, including muscle strengthening, maintaining the range of movement in the joints, reducing strain on the joints, etc., is also creating a positive outlook for the market. Furthermore, the emerging popularity of biological response modifiers, such as anakinra and tocilizumab, for treating the ailment since they block the activity of cytokines associated with the condition and prevent the progression of the illness, is expected to drive the Still's disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Still’s disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Still’s disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Still’s disease market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Still's disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Still's disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current Still's disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Still's disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Still's disease market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Still's disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of Still's disease across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Still's disease by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Still's disease by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with Still's disease across the seven major markets?
• What is the size of the Still's disease patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Still's disease?
• What will be the growth rate of patients across the seven major markets?
   

Still's Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Still's disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Still's disease market?
• What are the key regulatory events related to the Still's disease market?
• What is the structure of clinical trial landscape by status related to the Still's disease market?
• What is the structure of clinical trial landscape by phase related to the Still's disease market?
• What is the structure of clinical trial landscape by route of administration related to the Still's disease market?